Multiple Myeloma

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, myelodysplastic syndrome, breast cancer, colorectal cancer, and cervical cancer.

The FDA has approved Darzalex Faspro plus VRd for select multiple myeloma and several applications are under regulatory review in lung and GI cancers.

Sikander Ailawadhi, MD, and Beth Faiman, CNP, PhD, discuss the ongoing development of subcutaneous isatuximab administration via an on-body injector for patients with multiple myeloma.

IBI3003 received fast track designation from the regulatory agency in the setting of relapsed/refractory multiple myeloma.

Andrew Yee, MD, and Krina Patel, MD, MSc, discuss up-and-coming oral PI combination regimens in relapsed/refractory multiple myeloma.

Marc J. Braunstein, MD, PhD, discusses the clinical implications of the FDA approval of subcutaneous daratumumab with VRd for newly diagnosed multiple myeloma, ineligible ASCT.

The FDA has approved daratumumab and hyaluronidase plus VRd for adult patients with newly diagnosed multiple myeloma who are not eligible for ASCT.

Andrew Yee, MD, and Krina Patel, MD, MSc, discuss updates to the NCCN guidelines and key data updates in relapsed/refractory multiple myeloma.

Natalie Callander, MD, discusses the role of ALC monitoring in the management of relapsed/refractory multiple myeloma following CAR T-cell therapy.

Shaji Kumar, MD, shares phase 1 data from the CAMMA 1 trial evaluating cevostamab alone or in different combinations in relapsed/refractory myeloma.

Peter Voorhees, MD, discussed significance of the FDA approval of daratumumab and hyaluronidase for adult patients with high-risk smoldering multiple myeloma.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, breast cancer, and colorectal cancer.

The FDA issued a CRL for tabelecleucel in EBV+ PTLD, a BLA was submitted for an ivonescimab regimen in EGFR-mutated NSCLC, and more.

Dr Banerjee discussed the potential of CELMoDs for multiple myeloma management, highlighting their superior efficacy and safety compared with IMiDs.

Teclistamab monotherapy significantly improved PFS and OS vs standard-of-care therapy in relapsed/refractory multiple myeloma as early as the second line.

Hans Lee, MD, discusses the role of the CoMMit consortium as a collaborative forum shaping the future of multiple myeloma research.

Rahul Banerjee, MD, FACP, discusses key considerations and unanswered questions regarding the selection between KRd and VRd in newly diagnosed myeloma.

Luciano Costa, MD, discusses teclistamab plus daratumumab vs investigator’s choice of DPd/DVd in patients with relapsed or refractory multiple myeloma.

The top 5 OncLive TV videos of the week cover insights in lung cancer, bladder cancer, gastrointestinal cancer, and multiple myeloma.

Bone marrow Immune Atlas in myeloma linked immune system/tumor interactions with disease aggressiveness, potentially improving prognosis and risk stratification.

Noa Biran, MD, highlighted the real-world use of the SKY92 gene expression profiling assay for multiple myeloma risk stratification.

The EMA is reviewing a Type II variation application to expand teclistamab’s label for use with SC daratumumab in relapsed/refractory myeloma.

Here is your Q1 2026 preview spotlighting 5 FDA decisions to watch, including upcoming PDUFAs for tabelecleucel, pembrolizumab, and more.

The top 5 OncLive TV videos of the week cover insights in leukemia, lung cancer, multiple myeloma, indolent systemic mastocytosis, and pancreatic cancer.

Saad Z. Usmani, MD, MBA, FACP, FASCO, is renowned leader whose work has helped redefine treatment standards and extend the lives of patients worldwide.